![](/fileadmin/Content/NewsAndStories/2024/Bildschirmfoto_2024-07-09_um_09.31.12.png)
EMA-Gate: PharmaMar wins suit against EMA
The European Commission has corrected its decision C(2018) 4831 from 2018 not to grant marketing authorisation for Aplidin (plitidepsin), a peptidic...
![](/fileadmin/_processed_/csm_Fundus_-_diabetic_retinopathy_c83d88301e.png)
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
With the strategic acquisition,which has been unanimously approved by the EyeBio Board of Directors, MSD will take over Eyebiotech's clinical...
![](/fileadmin/_processed_/csm_Iqvia-obesity_pipeline_0680784a7f.png)
AstraZeneca puts step into obesity market
SixPeaks Bio, launched with US$30m in Series A funding led by Versant Ventures, which is known for its build to buy strategy, and announced a...
![](/fileadmin/_processed_/csm_SBA__c__Elvin_YilmazElvin_Yilmaz.jpg__a5edabbb67.jpg)
Swiss Biotech Report reporting record turnover
The Swiss Biotech Report 2024 commissioned by the Swiss Biotech Association and co-published with EY on the occasion of the Swiss Biotech Day...
![](/fileadmin/_processed_/csm_EBC_c_CDC_7b5c041c11.png)
Hornet Therapeutics reports first data of EBV-triggered disease blocker
Hornet Therapeutics Ltd that was spun out in 2020 from the group of Christoph Hess (now University Cambridge) at University Basel, has...
![](/fileadmin/_processed_/csm_Ipsen_headquarters.__c__Ipsen_SA_865320fa5c.jpg)
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...
![](/fileadmin/_processed_/csm_SFactory01_Launch_044ec847f4.png)
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...